Venus Medtech (Hangzhou) ( ) - 株価, ニュースと分析SEHK:2500

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

2500 株式概要

Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.

会社概要

2500 ファンダメンタル分析
スノーフレーク・スコア
評価	3/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

当社が推定した公正価値より23.4%で取引されている

収益は年間31.93%増加すると予測されています

リスク分析

株式の流動性は非常に低い

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Venus Medtech (Hangzhou) Inc. 競合他社

Acotec Scientific Holdings

SEHK:6669

HK$2.1b

Gaush Meditech

SEHK:2407

HK$2.0b

Sisram Medical

SEHK:1696

HK$1.7b

MicroPort CardioFlow Medtech

SEHK:2160

HK$2.0b

価格と性能

の歴代最高値、変動、値下がりまとめVenus Medtech (Hangzhou)
過去の株価
現在の株価	HK$5.62
52週高値	HK$14.94
52週安値	HK$3.74
ベータ	0.55
11ヶ月の変化	0%
3ヶ月変化	-0.71%
1年変化	-61.61%
33年間の変化	-92.66%
5年間の変化	n/a
IPOからの変化	-86.95%

Recent updates

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08

株主還元

	2500	HK Medical Equipment	HK 市場
7D	0%	-3.9%	1.9%
1Y	-61.6%	-43.6%	2.1%

業界別リターン: 2500過去 1 年間で-42.9 % の収益を上げたHong Kong Medical Equipment業界を下回りました。

リターン対市場: 2500は、過去 1 年間で-2 % のリターンを上げたHong Kong市場を下回りました。

価格変動

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.2%
Market Average Movement	7.2%
10% most volatile stocks in HK Market	15.4%
10% least volatile stocks in HK Market	3.7%

安定した株価: 2500過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間の2500のボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2009	1,006	Lin Haosheng Lim	www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. 基礎のまとめ

Venus Medtech (Hangzhou) の収益と売上を時価総額と比較するとどうか。
2500 基礎統計学
時価総額	HK$2.46b
収益（TTM）	-HK$1.31b
売上高(TTM)	HK$491.35m

5.0x

P/Sレシオ

-1.9x

PER（株価収益率

2500 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
2500 損益計算書（TTM）
収益	CN¥452.11m
売上原価	CN¥101.03m
売上総利益	CN¥351.07m
その他の費用	CN¥1.56b
収益	-CN¥1.21b

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-2.76
グロス・マージン	77.65%
純利益率	-267.18%
有利子負債／自己資本比率	23.4%

2500 の長期的なパフォーマンスは？

過去の実績と比較を見る

2500 株式概要

報酬

リスク分析

Venus Medtech (Hangzhou) Inc. 競合他社

SEHK:6669

HK$2.1b

SEHK:2407

HK$2.0b

SEHK:1696

HK$1.7b

SEHK:2160

HK$2.0b

価格と性能

最新ニュース

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Recent updates

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Consensus EPS estimates fall by 24%

No longer forecast to breakeven

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

Forecast to breakeven in 2025

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Forecast breakeven date pushed back to 2023

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

GM & Executive Director recently bought HK$35m worth of stock

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

National Medical Products Administration of China Approves Venus Medtech's VenusA-Plus Transcatheter Prosthetic Aortic Valve Replacement System - Retrievable Delivery System